AFib ablation slashed progression risk; FDA panel pans empagliflozin for type 1 diabetes
By Mitchel Zoler
AFib ablation cut the rate of paroxysmal to persistent arrhythmia progression by 89%, compared with medical management.
You can take the MDedge Podcasts survey by clicking here.
Panelists voted 14-2 against the application and criticized the limited data supporting the application.
One of the College’s suggestions is for the Medicare Part D low-income subsidy program to be modified.
The standard premium will climb 6.7% in 2020.
The results were observed for 10 mg methotrexate per week at 3 months and 12 months.